WHO Drug Information Vol. 15, No. 2, 2001
(2001; 91 pages) View the PDF document
Table of Contents
Open this folder and view contentsPersonal Perspectives
Open this folder and view contentsReports on Individual Drugs
Open this folder and view contentsVaccines and Biomedicines
Open this folder and view contentsCurrent Topics
Open this folder and view contentsGeneral Information
Close this folderRegulatory and Safety Matters
View the documentNew Zealand and Australia: joint medicines regulatory body
View the documentBupropion safety information
View the documentBupropion update
View the documentItraconazole and congestive heart failure
View the documentTerbinafine and hepatic failure
View the documentPaediatric amiodarone labelling changes
View the documentCerivastatin: marketing discontinued
View the documentPhenylpropanolamine withdrawn from market
View the documentCounterfeit filgrastim
View the documentOxycodone: strengthened warning
View the documentNesiritide for heart failure
View the documentOprelvekin: paediatric safety information
View the documentPeginterferon alfa-2b combined use: new labelling
View the documentRibavirin for combined use
View the documentSleep attacks with pramipexole and ropinirole
View the documentRosiglitazone-associated hepatic and cardiovascular events
View the documentClarithromycin: labelling change
View the documentHerbal OTC remedy and hepatic dysfunction
View the documentAntipsychotics and high prolactin
View the documentSildenafil: not for use with nitrates
View the documentPropofol, heart failure and high dosages
View the documentBupropion and seizures
View the documentNeurotoxicity with aciclovir and valaciclovir
View the documentRevised labelling for levocarnitine
View the documentAvoid trastuzumab and anthracyclines
Open this folder and view contentsATC/DDD Classification
Open this folder and view contentsEssential Drugs
Open this folder and view contentsRecent Publications and Sources of Information
View the documentInternational Nonproprietary Names for Pharmaceutical Substances (INN)
View the documentDénominations communes internationales des Substances pharmaceutiques (DCI)
View the documentDenominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)
View the documentAmendments to previous lists/Modifications apportées aux listes antérieures/Modificaciones a las listas anteriores
View the documentAnnexes

Phenylpropanolamine withdrawn from market

Canada - Following a safety assessment, Health Canada has advised that drug products containing phenylpropanolamine are being withdrawn from the market. Following a review of information, it was concluded that use of this ingredient in prescription and nonprescription medicines cannot be justified, no matter how rare the event of a possible haemorrhagic stroke.

A regulatory process to remove all products containing PPA from the Canadian market has been initiated. A number of manufacturers have indicated that they are reformulating their cough and cold, sinus and allergy medications with safe and effective alternatives.

Reference: Health Canada Advisory, 2001-61, 30 May 2001.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017